Therefore, we launched an investigator-initiated, Simon’s two-stage design trial of neoadjuvant sintilimab combined with carboplatin and nab-paclitaxel (nab-PC) in early-stage EGFR-mutant NSCLC (ClinicalTrials.gov: NCT05244213). This evidence concerns the gene EGFR and non-small cell lung carcinoma.